- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
- Compugen to Participate in Two Upcoming Investor Conferences
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
- Compugen Reports Fourth Quarter and Full Year 2023 Results
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
More ▼
Key statistics
As of last trade Compugen Ltd (CGEN:NAQ) traded at 2.08, -31.36% below its 52-week high of 3.03, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.22 |
Low | 2.08 |
Bid | 2.07 |
Offer | 2.08 |
Previous close | 2.16 |
Average volume | 293.11k |
---|---|
Shares outstanding | 89.53m |
Free float | 84.72m |
P/E (TTM) | -- |
Market cap | 193.39m USD |
EPS (TTM) | -0.2159 USD |
Data delayed at least 15 minutes, as of May 03 2024 18:29 BST.
More ▼